Metastatic Breast Cancer

Oncology
82
Pipeline Programs
30
Companies
50
Clinical Trials
17 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
18
17
32
1
10
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1959%
Monoclonal Antibody
619%
ADC
619%
Cell Therapy
13%
+ 79 programs with unclassified modality

On Market (4)

Approved therapies currently available

E
HALAVENApproved
eribulin mesylate
Eisai
intravenous2010
Roche
ITOVEBIApproved
inavolisib
Roche
Kinase Inhibitor [EPC]oral2024
Roche
PERJETAApproved
pertuzumab
Roche
HER2/neu Receptor Antagonist [EPC]single-use2012
Eli Lilly and Company
VERZENIOApproved
abemaciclib
Eli Lilly and Company
Kinase Inhibitor [EPC]oral2017

Competitive Landscape

40 companies ranked by most advanced pipeline stage

E
13 programs
3
4
2
1
Eribulin MesylatePhase 31 trial
pertuzumabPhase 3Monoclonal Antibody1 trial
E7070Phase 21 trial
EribulinPhase 21 trial
EribulinPhase 21 trial
+8 more programs
Active Trials
NCT01240421Approved For MarketingEst. Nov 2014
NCT03245112Unknown500Est. Dec 2017
NCT02790320Completed112Est. Nov 2012
+9 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
5 programs
3
1
VERZENIO(Abemaciclib)Phase 2Small Molecule5 trials
IMC-A12Phase 21 trial
LY2523355Phase 24 trials
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008N/A
Implementing Patients´ Competence in Oral Breast Cancer TherapyN/A1 trial
Active Trials
NCT04030728Unknown212Est. Dec 2021
NCT02792725Approved For Marketing
NCT03763604Approved For Marketing
+8 more trials
Roche
RocheSTAVANGER NORWAY, Norway
4 programs
3
1
ITOVEBI(Inavolisib)Phase 3Small Molecule2 trials
PertuzumabPhase 3Monoclonal Antibody1 trial
Trastuzumab EmtansinePhase 3ADC1 trial
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008N/A
Active Trials
NCT07347600Recruiting500Est. Sep 2029
NCT05894239Recruiting230Est. Dec 2032
NCT00567190Completed808Est. Nov 2018
+1 more trials
CT
3 programs
1
1
1
TQB2102 InjectionPhase 31 trial
TQB2930 for injectionPhase 1/21 trial
Trastuzumab for injectionPhase 11 trial
Active Trials
NCT05765357CompletedEst. Oct 2017
NCT06202261RecruitingEst. Oct 2027
NCT07008976RecruitingEst. Dec 2028
Celltrion
CelltrionKorea - Incheon
2 programs
1
1
CT-P6Phase 31 trial
CT-P6Phase 1/21 trial
Active Trials
NCT01084863Completed143Est. Dec 2023
NCT01084876Completed475Est. Mar 2015
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
ESG401Phase 31 trial
Active Trials
NCT06383767RecruitingEst. Jul 2028
Spexis
SpexisSwitzerland - Allschwil
1 program
1
EribulinPhase 31 trial
Active Trials
NCT03786094Terminated432Est. Oct 2021
OD
1 program
1
Pegylated liposomal doxorubicinPhase 3
Amgen
AmgenTHOUSAND OAKS, CA
3 programs
1
1
G-CSFPhase 2/35 trials
SorafenibPhase 2Small Molecule1 trial
PalbociclibN/ASmall Molecule
Active Trials
NCT00632541Terminated18Est. Mar 2009
NCT00002126Completed250
NCT00002255Completed
+3 more trials
Pfizer
12 programs
1
1
3
PalbociclibPhase 2Small Molecule1 trial
SU11248Phase 21 trial
SamuraciclibPhase 2Small Molecule1 trial
CapecitabinePhase 1/25 trials
PalazestrantPhase 11 trial
+7 more programs
Active Trials
NCT05559528Unknown300Est. Dec 2024
NCT06161181Completed94Est. May 2024
NCT03007641Completed100Est. Apr 2019
+12 more trials
DS
Daiichi SankyoChina - Shanghai
8 programs
1
3
3
Patritumab deruxtecanPhase 2ADC1 trial
U3-1402Phase 21 trial
U3-1402Phase 23 trials
Patritumab DeruxtecanPhase 1/2ADC1 trial
Trastuzumab deruxtecanPhase 1/2ADC1 trial
+3 more programs
Active Trials
NCT04556773Active Not Recruiting138Est. Jun 2026
NCT02980341Completed182Est. Sep 2023
NCT04538742Active Not Recruiting245Est. Jan 2030
+6 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
5 programs
1
PaclitaxelPhase 25 trials
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008N/A
NoneN/A2 trials
PalbociclibN/ASmall Molecule
Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.N/A1 trial
Active Trials
NCT06388616Completed30Est. Sep 2024
NCT04857619Completed763Est. Oct 2022
NCT06417801Recruiting70Est. Dec 2025
+5 more trials
Genentech
4 programs
3
LetrozolePhase 2Small Molecule
SorafenibPhase 2Small Molecule
bevacizumabPhase 2Monoclonal Antibody1 trial
Understanding value in Metastatic Breast CancerN/A1 trial
Active Trials
NCT03257917Completed100Est. Jul 2019
NCT00434356Terminated46
Novartis
NovartisBASEL, Switzerland
3 programs
1
1
BEZ235Phase 21 trial
PalazestrantPhase 11 trial
RibiciclibN/ASmall Molecule1 trial
Active Trials
NCT05141240Completed4,650Est. Jun 2020
NCT07085767Recruiting1,000Est. Jan 2032
NCT01288092Withdrawn0
Stemline Therapeutics
3 programs
1
1
1
ElacestrantPhase 21 trial
ElacestrantPhase 1/21 trial
RAD1901Phase 11 trial
Active Trials
NCT02650817Completed16Est. Oct 2019
NCT07198724Not Yet Recruiting65Est. Jun 2038
NCT05596409Active Not Recruiting61Est. Jul 2027
CP
Chugai PharmaJapan - Tokyo
3 programs
3
Induction therapyPhase 21 trial
PaclitaxelPhase 21 trial
bevacizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06793553Recruiting106Est. Sep 2028
NCT01989780Completed160Est. Jun 2019
NCT00467012Completed122Est. Sep 2011
Pierre Fabre
Pierre FabreFrance - Aignan
2 programs
1
VinorelbinePhase 21 trial
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008N/A
Active Trials
NCT03007992CompletedEst. Mar 2019
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
1
WX-671Phase 21 trial
Genomic Profiling / SequencingN/A1 trial
Active Trials
NCT05652569Recruiting5,000Est. Dec 2030
NCT00615940Completed132Est. Apr 2012
Bayer
BayerLEVERKUSEN, Germany
2 programs
1
LonaprisanPhase 21 trial
PalbociclibN/ASmall Molecule
Active Trials
NCT00555919Completed68Est. Mar 2011
Bristol Myers Squibb
2 programs
1
1
Irinotecan + CarboplatinPhase 21 trial
NivolumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT03807765Completed14Est. Mar 2025
NCT00248287Active Not Recruiting154Est. Dec 2026
Carrick Therapeutics
Carrick TherapeuticsIreland - Dublin
2 programs
1
1
SamuraciclibPhase 2Small Molecule
SamuraciclibPhase 1/2Small Molecule1 trial
Active Trials
NCT05963997Active Not RecruitingEst. Feb 2026
Allarity Therapeutics
2 programs
2
Ixabepilone InjectionPhase 21 trial
PARP inhibitor 2X-121Phase 21 trial
Active Trials
NCT04796324SuspendedEst. Nov 2025
NCT03562832CompletedEst. Aug 2024
Corcept Therapeutics
1 program
1
EnzalutamidePhase 2
Taiho Oncology
Taiho OncologyNJ - Princeton
1 program
1
FutibatinibPhase 2Small Molecule1 trial
Active Trials
NCT04024436TerminatedEst. Sep 2023
GS
Gilead SciencesFOSTER CITY, CA
6 programs
2
CapecitabinePhase 1/2
CapecitabinePhase 1/21 trial
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008N/A
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008N/A1 trial
PalbociclibN/ASmall Molecule
+1 more programs
Active Trials
NCT03275311Recruiting40,000Est. Dec 2026
NCT03424005Recruiting792Est. Sep 2030
M&
3 programs
2
MK-0752, Docetaxel, PegfilgrastimPhase 1/21 trial
Patritumab DeruxtecanPhase 1/2ADC
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008N/A
Active Trials
NCT00645333Completed30Est. Oct 2012
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
1
ZongertinibPhase 1/2Small Molecule1 trial
Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the N/A1 trial
Active Trials
NCT07342309Active Not Recruiting7,933Est. Jun 2026
NCT06324357Recruiting768Est. Jan 2029
B
ByondisNetherlands - Nijmegen
1 program
1
BYON5667 & SYD985Phase 1/21 trial
Active Trials
NCT04983238CompletedEst. Jun 2023
Alliance Pharmaceuticals
2 programs
2
AdHer-2/neu transduced dendritic cellsPhase 11 trial
adenoviral vector encoding rat Her-2/neuPhase 11 trial
Active Trials
NCT00162929Completed5Est. May 2012
NCT00307229Completed8Est. May 2012
Acrotech Biopharma
Acrotech BiopharmaNJ - East Windsor
2 programs
2
RibociclibPhase 1Small Molecule
TalazoparibPhase 1

+10 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Eli Lilly and CompanyAbemaciclib
Eli Lilly and CompanyAbemaciclib
Eli Lilly and CompanyAbemaciclib
Eli Lilly and CompanyAbemaciclib
AstraZenecaPaclitaxel
NovartisPalazestrant
AstraZenecaPaclitaxel
Chia Tai TianQing Pharmaceutical GroupTQB2102 Injection
AstraZenecaPaclitaxel
Qilu PharmaceuticalESG401
AstraZenecaPaclitaxel
AstraZenecaPaclitaxel
RocheInavolisib
Eli Lilly and CompanyAbemaciclib
Eli Lilly and CompanyAbemaciclib

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 23,268 patients across 50 trials

NCT05362760Eli Lilly and CompanyAbemaciclib

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

Start: Apr 2022Est. completion: Apr 2029300 patients
Phase 4Recruiting
NCT04707196Eli Lilly and CompanyAbemaciclib

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

Start: Feb 2021Est. completion: Jan 2023200 patients
Phase 4Completed
NCT03988114Eli Lilly and CompanyAbemaciclib

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Start: Sep 2019Est. completion: Mar 20230
Phase 4Withdrawn
NCT04031885Eli Lilly and CompanyAbemaciclib

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Start: Aug 2019Est. completion: Aug 20204 patients
Phase 4Terminated
NCT07218809AstraZenecaPaclitaxel

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Start: Dec 2025Est. completion: May 20301,100 patients
Phase 3Recruiting
NCT07085767NovartisPalazestrant

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Start: Nov 2025Est. completion: Jan 20321,000 patients
Phase 3Recruiting
NCT07044336AstraZenecaPaclitaxel

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Start: Aug 2025Est. completion: Jul 2029700 patients
Phase 3Recruiting
NCT07008976Chia Tai TianQing Pharmaceutical GroupTQB2102 Injection

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

Start: Jul 2025Est. completion: Dec 2028
Phase 3Recruiting
NCT06692738AstraZenecaPaclitaxel

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Start: Nov 2024Est. completion: Oct 2029880 patients
Phase 3Recruiting
NCT06383767Qilu PharmaceuticalESG401

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Start: Jul 2024Est. completion: Jul 2028
Phase 3Recruiting
NCT06346392AstraZenecaPaclitaxel

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Start: Mar 2024Est. completion: Sep 2026572 patients
Phase 3Recruiting
NCT05984277AstraZenecaPaclitaxel

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

Start: Oct 2023Est. completion: Mar 20291,200 patients
Phase 3Active Not Recruiting
NCT05894239RocheInavolisib

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Start: Sep 2023Est. completion: Dec 2032230 patients
Phase 3Recruiting
NCT05169567Eli Lilly and CompanyAbemaciclib

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Start: Mar 2022Est. completion: Dec 2027368 patients
Phase 3Active Not Recruiting
NCT04975308Eli Lilly and CompanyAbemaciclib

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Start: Oct 2021Est. completion: Aug 2027874 patients
Phase 3Active Not Recruiting
NCT04740918RocheTrastuzumab Emtansine

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Start: Jun 2021Est. completion: Jun 202496 patients
Phase 3Terminated
NCT04752332Eli Lilly and CompanyAbemaciclib

A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

Start: May 2021Est. completion: Jun 2024111 patients
Phase 3Terminated
NCT04565054Eli Lilly and CompanyAbemaciclib

Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Start: Sep 2020Est. completion: Jul 20291,260 patients
Phase 3Active Not Recruiting
NCT03997123AstraZenecaPaclitaxel

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Start: Jun 2019Est. completion: Mar 2026923 patients
Phase 3Active Not Recruiting
NCT03786094SpexisEribulin

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Start: May 2019Est. completion: Oct 2021432 patients
Phase 3Terminated
NCT03155997Eli Lilly and CompanyAbemaciclib

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

Start: Jul 2017Est. completion: May 20295,637 patients
Phase 3Active Not Recruiting
NCT02763566Eli Lilly and CompanyAbemaciclib

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

Start: Dec 2016Est. completion: Mar 2028463 patients
Phase 3Active Not Recruiting
NCT02344472Eisaipertuzumab

Detect V / CHEVENDO (Chemo vs. Endo)

Start: Sep 2015Est. completion: Jan 2025271 patients
Phase 3Active Not Recruiting
NCT02246621Eli Lilly and CompanyAbemaciclib

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Start: Nov 2014Est. completion: Dec 2026493 patients
Phase 3Active Not Recruiting
NCT02152631Eli Lilly and CompanyAbemaciclib

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

Start: Oct 2014Est. completion: Dec 2026453 patients
Phase 3Active Not Recruiting
NCT01084876CelltrionCT-P6

Demonstrate Efficacy and Safety of Metastatic Breast Cancer

Start: Jun 2010Est. completion: Mar 2015475 patients
Phase 3Completed
NCT00567190RochePertuzumab

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

Start: Feb 2008Est. completion: Nov 2018808 patients
Phase 3Completed
NCT00337103EisaiEribulin Mesylate

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Start: Sep 2006Est. completion: Dec 20171,276 patients
Phase 3Completed
NCT00322452AstraZenecaPaclitaxel

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia

Start: Mar 2006Est. completion: Jun 20101,329 patients
Phase 3Completed
NCT00006049AstraZenecaPaclitaxel

ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Start: May 2000
Phase 3Unknown
NCT03706365Eli Lilly and CompanyAbemaciclib

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Start: Nov 2018Est. completion: Jun 2026393 patients
Phase 2/3Active Not Recruiting
NCT01196741AstraZenecaPaclitaxel

Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

Start: Mar 2011Est. completion: Jan 2014107 patients
Phase 2/3Completed
NCT00169104AmgenG-CSF

Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function

Start: Jul 2002Est. completion: Mar 200923 patients
Phase 2/3Terminated
NCT00000626AmgenG-CSF

Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

Est. completion: Feb 199927 patients
Phase 2Completed
NCT00002126AmgenG-CSF

A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.

250 patients
Phase 2Completed
NCT06413706Eli Lilly and CompanyAbemaciclib

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Start: Oct 2024Est. completion: Feb 202845 patients
Phase 2Active Not Recruiting
NCT06366347Eli Lilly and CompanyAbemaciclib

ALPINE: Maintenance Letrozole/Abemaciclib

Start: Sep 2024Est. completion: Mar 202932 patients
Phase 2Recruiting
NCT06793553Chugai PharmaInduction therapy

Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

Start: Sep 2024Est. completion: Sep 2028106 patients
Phase 2Recruiting
NCT06448754AstraZenecaPaclitaxel

Volrustomig Priming Regimens Exploratory Phase II Platform Study

Start: Aug 2024Est. completion: Jul 2027180 patients
Phase 2Recruiting
NCT06535607AstraZenecaPaclitaxel

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Start: Aug 2024Est. completion: Nov 2028110 patients
Phase 2Recruiting
NCT05800275PfizerCapecitabine

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

Start: Dec 2023Est. completion: Jun 202730 patients
Phase 2Recruiting
NCT05872204Eli Lilly and CompanyAbemaciclib

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

Start: Nov 2023Est. completion: Jan 2028100 patients
Phase 2Recruiting
NCT06016387PfizerCapecitabine

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

Start: Nov 2023Est. completion: Oct 202830 patients
Phase 2Recruiting
NCT05865990Daiichi SankyoPatritumab deruxtecan

HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease

Start: Nov 2023Est. completion: Oct 202663 patients
Phase 2Active Not Recruiting
NCT05963984PfizerSamuraciclib

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

Start: Nov 2023Est. completion: Aug 202560 patients
Phase 2Completed
NCT05501704Eli Lilly and CompanyAbemaciclib

ETHAN - ET for Male BC

Start: Oct 2023Est. completion: Apr 203660 patients
Phase 2Recruiting
NCT06001762Eli Lilly and CompanyAbemaciclib

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Start: Oct 2023Est. completion: Jan 202790 patients
Phase 2Active Not Recruiting
NCT05596409Stemline TherapeuticsElacestrant

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

Start: May 2023Est. completion: Jul 202761 patients
Phase 2Active Not Recruiting
NCT05440786Eli Lilly and CompanyAbemaciclib

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Start: Sep 2022Est. completion: Sep 202846 patients
Phase 2Active Not Recruiting
NCT05227131PfizerCapecitabine

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer

Start: May 2022Est. completion: Oct 20240
Phase 2Withdrawn

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
1h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
3h ago

Executive Director, I.T.- Head of Security Architecture, Engineering, and Delivery

Gilead Sciences
United States - California - Foster City
17h ago
$281K - $364K/yr

Sr Research Associate, Analytical Operations

Gilead Sciences
United States - California - Oceanside
17h ago
$86K - $112K/yr

Associate Director, Insights & Analytics Platform Technology Lead

Gilead Sciences
United States - California - Foster City
17h ago
$196K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

10 late-stage (Phase 3) programs — potential near-term approvals
17 actively recruiting trials targeting 23,268 patients
30 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)